An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
This is an open label extension study in subjects who are 6 years of age or older with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002). This study is designed to evaluate the safety and describe the efficacy of rivipansel as treatment for one or more vaso-occlusive crisis (VOC) events in hospitalized subjects with SCD.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20001, United States
Atlanta, Georgia 30303, United States
Atlanta, Georgia 30322, United States
Atlanta, Georgia 30342, United States
Baltimore, Maryland 21201, United States
Baltimore, Maryland 21287-6180, United States
Boston, Massachusetts 02115, United States
Jackson, Mississippi 39216, United States
New Brunswick, New Jersey 08901, United States
Brooklyn, New York 11203, United States
Cincinnati, Ohio 45219, United States
Columbus, Ohio 43210, United States
Charleston, South Carolina 29425, United States
Richmond, Virginia 23298, United States
Richmond, Virginia 23298, United States